Comparing different doses of prilocaine for knee surgery anesthesia
Intrathecal Hyperbaric Prilocaine in Adult Patients Undergoing Knee Arthroscopy, a Randomized Controlled Trail
This study is testing different doses of a numbing medicine for knee surgery to see which one helps patients recover faster and feel better afterward.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06703580 on ClinicalTrials.gov |
What this trial studies
This randomized trial aims to evaluate the effectiveness of three different doses of hyperbaric prilocaine 2% (40, 50, and 60 mg) administered through spinal anesthesia in patients undergoing knee arthroscopy. The primary focus is to compare the time it takes for patients to void after the procedure. Secondary outcomes include recovery times for motor and sensory functions, discharge times from the post-anesthesia care unit, and monitoring for any complications such as itching or nausea. The study targets day case surgeries, making it relevant for outpatient procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-60 years, classified as American Society of Anesthesiologists physical status I-II, who are scheduled for knee arthroscopy.
Not a fit: Patients with coagulopathy, infections at the injection site, or allergies to prilocaine may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could optimize anesthesia protocols, leading to quicker recovery times and improved patient satisfaction after knee arthroscopy.
How similar studies have performed: Previous studies have shown promising results with similar local anesthetic approaches, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients (male/female, American Society of Anesthesiologists physical status I-II, age: 18-60 years) undergoing knee arthroscopy will be eligible for the study. - Exclusion Criteria: 1. Coagulopathy and other bleeding disorders (INR more than 1.4 and platelet less than 80000) 2. Patient refusal. 3. Infection at the site of injection. 4. Allergies against prilocaine. 5. Increased intracranial pressure. 6. Severe MS and AS. 7. Sever hypovolemia.
Where this trial is running
Cairo
- Kasr Al Ainy Hospital , Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Alaa M Taha, lecturer
- Email: alaa.taha@kasralainy.edu.eg
- Phone: +201276143115
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.